

References

Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. *Proceedings of the National Academy of Sciences*, 100(7), 3983-3988.

Amé, J. C., Spenlehauer, C., & de Murcia, G. (2004). The PARP superfamily. *Bioessays*, 26(8), 882-893.

Au, A., Ankathil, R., Goh, A. S., Wahid, F. S. A., & Aziz, A. (2012). Influence of ABCB1 C3435T and ABCG2 C421A Gene Polymorphisms in Response to Imatinib Mesylate in Chronic Myeloid Leukemia Patients. *International Conference on Clean and Green Energy*, 27, 118-123.

Augustin, H. G. (2003). Angiogeneseforschung—Quo vadis?. *Der Ophthalmologe*, 100(2), 104-110.

Bast, R. C., Kufe, D. W., Pollock, R. E., Weichselbaum, R. R., Holland, J. F., & Frei, E. (2000). *Holland-frei cancer medicine*.

Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. *Nature Reviews Cancer*, 8(8), 592-603.

Bissett, D., O'Byrne, K. J., Von Pawel, J., Gatzemeier, U., Price, A., Nicolson, M., ... & Shepherd, F. A. (2005). Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. *Journal of clinical oncology*, 23(4), 842-849.

Bix, G., Castello, R., Burrows, M., Zoeller, J. J., Weech, M., Iozzo, R. A., ... & Iozzo, R. V. (2006). Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. *Journal of the National Cancer Institute*, 98(22), 1634-1646.